The recent surge has been due to the tremendous growth Lilly has achieved due to its highly popular GLP-1 drugs, including ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra Investments. In this article, we will ...

Fred Alger Management, an investment management company, released its “Alger Spectra Fund” fourth quarter 2024 investor ...

While the pharma stock's valuation may not be cheap (it trades at more than 80 times earnings), it's a premium that's ...

Eli Lilly (NYSE: LLY) has become a beast in healthcare ... which weren't great either. For Mounjaro, the diabetes treatment, Q4 sales will total $3.5 billion -- well short of analyst estimates ...

the stock is very cheap. Given its valuation and the growth still in front of it with GLP-1 drugs, investors can look to buy the dip in Eli Lilly stock. JPMorgan Chase is an advertising partner of ...

Eli Lilly has its sights set on approval ... Gavin Newsom's (D) plan to produce cheap, generic insulin is far behind schedule, industry experts said. (CalMatters) In related news, a federal ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're about to lose access.

The FDA is about to make it a lot harder to get cheap weight-loss drugs Jessica ... the brand-name version made by Eli Lilly. DeBenedetto, now 43, tells me she's been prediabetic since her 20s ...